The Innovative Medicines Initiative's DRIVE-AB project joins the fray of task forces working to reinvigorate interest in antibiotics by developing reimbursement models that delink revenue from sales volume.
Access options
Subscribe to Journal
Get full journal access for 1 year
$259.00
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Momentum builds around new antibiotic business models. Nat Rev Drug Discov 13, 711–713 (2014). https://doi.org/10.1038/nrd4455
Published:
Issue Date:
Further reading
-
Antibiotics: past, present and future
Current Opinion in Microbiology (2019)
-
Introduction: DRIVE-AB’s definitions and indicators to monitor responsible antibiotic use
Journal of Antimicrobial Chemotherapy (2018)
-
Peripheral modifications of [Ψ[CH2NH]Tpg4]vancomycin with added synergistic mechanisms of action provide durable and potent antibiotics
Proceedings of the National Academy of Sciences (2017)
-
The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public–private partnerships for the development of new strategies to tackle antibiotic resistance
Journal of Antimicrobial Chemotherapy (2016)
-
2014 FDA drug approvals
Nature Reviews Drug Discovery (2015)
